InvestorsHub Logo
Followers 253
Posts 17973
Boards Moderated 0
Alias Born 01/19/2006

Re: Whalatane post# 198118

Sunday, 06/23/2019 9:25:45 PM

Sunday, June 23, 2019 9:25:45 PM

Post# of 426185
Kiwi, to this day I have not read all of AMRN’s patents in that suit, nor their respective claims/specifications, nor their respective prosecution histories and mountains of prior art cited in each. All form part of the intrinsic record that the court will consider.

Early on, I posted that I would not enter opinions on the merits of litigation questions that others asked. It is not a function of anyone here to voice such opinions; that is a function of the federal judiciary, as those questions may arise. While I have 52 years of actual career experience(1964-2016) in assisting the federal judiciary resolve such questions, I no longer have those jobs as an employee of a federal appellate court, the CCPA( 1964-1973); as a PTO employee briefing and arguing cases before the CCPA and other trial and appeal courts in the D.C. circuit(1973-1986); or as a self-employed patent attorney hired as an expert witness to testify before judges and juries in ~150 patent infringement suits(1986=2016).

Rather I choose to skate along managing investments; with Amarin, I remain satisfied that Vascepa, with which I have 6+ years of personal experience, remains a new vehicle travelling on a new road to a new destination to achieve a new result not achieved before in me.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News